$7.86
-0.16-2%
Last update: Nov 10, 4:00 PM
Maravai LifeSciences Holdings Inc
MRVINASDAQ
Maravai LifeSciences rose 158.7% from $3.10 to $8.02, ahead of the S&P 500's +10.0%. Its worst day was Jan 28 (−10.0%), and its low came Mar 31 at $2.83.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Maravai LifeSciences shares rose 12.0%, while the S&P 500 fell 0.0%.
+12.0% · S&P 500 0.0%
Maravai LifeSciences shares rose 11.5%, while the S&P 500 rose 0.7%.
+11.5% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
EPS of $-0.04 beat the $-0.08 estimate on $49.9M revenue (est. $49.1M); FY revenue guidance of $200.0M–$210.0M against the $206.2M consensus.
+9.2% · S&P 500 −0.6%
Maravai LifeSciences closed at its lowest level of the year, 8.7% below where the year started.
−1.7% · S&P 500 +2.9%
EPS of $0.01 beat the $-0.05 estimate on $65.8M revenue (est. $53.3M); FY revenue guidance of $205.0M–$215.0M against the $205.0M consensus.
+23.1% · S&P 500 +0.8%
EPS of $-0.02 beat the $-0.05 estimate on $51.4M revenue (est. $48.8M); FY revenue guidance of $205.0M–$215.0M against the $210.4M consensus.
−0.3% · S&P 500 +0.6%
Maravai LifeSciences closed at its highest level of the year, 190.3% above where the year started.
+6.8% · S&P 500 +0.3%
EPS of $-0.03 beat the $-0.06 estimate on $45.9M revenue (est. $43.4M); FY revenue guidance of $212.0M–$216.0M against the $211.7M consensus.
−9.6% · S&P 500 −4.4%
Where it ended: a close of $8.02 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.04, revenue est. $51.2M).
Nothing in the past 12 months.
All MRVI dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MRVI and SPY from Benzinga historical bars. Not investment advice.
